1-3 of 3
Danelle James, MD MAS
Close
Sort by
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Susan O'Brien, MD, Samantha Jaglowski, MD MPH, John C. Byrd, MD, Rajat Bannerji, MD PhD, Kristie Blum, MD, Christopher P. Fox, MBChB, PhD, Richard R. Furman, MD, Peter Hillmen, Thomas J. Kipps, MD, Marco Montillo, MD, Jeff Sharman, MD, Sam Suzuki, MS, MBA, Danelle James, MD MAS, Alvina D. Chu, MD, Steven Coutre, MD
Journal: Blood
Blood (2015) 126 (23): 4153.
https://doi.org/10.1182/blood.V126.23.4153.4153
Published: 2015
Journal Articles

Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR).

Danelle James, MD, MAS, Esther D Avery, Ling Zhang, Jamie Gould, Andrew Greaves, Januario E. Castro, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3440.
https://doi.org/10.1182/blood.V114.22.3440.3440
Published: 2009